@article{383775809c0f430a924eaa56d81f4a4a,
title = "Cardiovascular disease in survivors of childhood cancer",
abstract = "A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.",
keywords = "Anthracycline, Cardio-oncology, Cardiotoxicity, Childhood cancer, Survivorship",
author = "Neha Bansal and Amdani, {Shahnawaz M.} and Hutchins, {Kelley K.} and Lipshultz, {Steven E.}",
note = "Funding Information: The preparation of this article was supported in part by grants from the National Institutes of Health (HL072705, HL078522, HL053392, CA127642, CA068484, HD052104, AI50274, HD52102, HL087708, HL079233, HL004537, HL087000, HL007188, HL094100, HL095127 and HD80002), the National Heart, Lung, and Blood Institute (R01 HL53392, R01 HL111459, R01 HL109090), the Children{\textquoteright}s Cardiomyopathy Foundation, the Women{\textquoteright}s Cancer Association, the Lance Armstrong Foundation, the STOP Children{\textquoteright}s Cancer Foundation, the Parker Family Foundation, the Scott Howard Fund, the Michael Garil Fund, Sofia{\textquoteright}s Hope, the Kyle John Rymiszewski Foundation. Publisher Copyright: Copyright {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2018",
doi = "10.1097/MOP.0000000000000675",
language = "English (US)",
volume = "30",
pages = "628--638",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "5",
}
